Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Ex-Vivo Treatment of Tumor Tissue Slices as a Predictive Preclinical Method to Evaluate Targeted Therapies for Patients with Renal Carcinoma.

Roelants C, Pillet C, Franquet Q, Sarrazin C, Peilleron N, Giacosa S, Guyon L, Fontanell A, Fiard G, Long JA, Descotes JL, Cochet C, Filhol O.

Cancers (Basel). 2020 Jan 17;12(1). pii: E232. doi: 10.3390/cancers12010232.

2.

[Geriatric medicine : Update 2019].

Heck GM, Lajoso S, Schneider R, Puttalaz P, Cochet C, Gagliano MA, Besse S, Costa AD, Musumeci V, Nguyen S, Büla C.

Rev Med Suisse. 2020 Jan 15;16(676-7):37-40. French.

PMID:
31961081
3.

Protein kinase CK2 contributes to placental development: physiological and pathological implications.

Abi Nahed R, Reynaud D, Lemaitre N, Lartigue S, Roelants C, Vaiman D, Benharouga M, Cochet C, Filhol O, Alfaidy N.

J Mol Med (Berl). 2020 Jan;98(1):123-133. doi: 10.1007/s00109-019-01855-0. Epub 2019 Dec 12.

PMID:
31832700
4.

Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.

Kufareva I, Bestgen B, Brear P, Prudent R, Laudet B, Moucadel V, Ettaoussi M, Sautel CF, Krimm I, Engel M, Filhol O, Borgne ML, Lomberget T, Cochet C, Abagyan R.

Sci Rep. 2019 Nov 4;9(1):15893. doi: 10.1038/s41598-019-52141-5.

5.

Feasibility of two-dimensional ultrasound shear wave elastography of human fetal lungs and liver: A pilot study.

Mottet N, Cochet C, Vidal C, Metz JP, Aubry S, Bourtembourg A, Eckman-Lacroix A, Riethmuller D, Pazart L, Ramanah R.

Diagn Interv Imaging. 2019 Aug 22. pii: S2211-5684(19)30180-9. doi: 10.1016/j.diii.2019.08.002. [Epub ahead of print]

PMID:
31447393
6.

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.

Bestgen B, Krimm I, Kufareva I, Kamal AAM, Seetoh WG, Abell C, Hartmann RW, Abagyan R, Cochet C, Le Borgne M, Engel M, Lomberget T.

J Med Chem. 2019 Feb 28;62(4):1803-1816. doi: 10.1021/acs.jmedchem.8b01766. Epub 2019 Feb 18.

PMID:
30689953
7.

2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.

Bestgen B, Kufareva I, Seetoh W, Abell C, Hartmann RW, Abagyan R, Le Borgne M, Filhol O, Cochet C, Lomberget T, Engel M.

J Med Chem. 2019 Feb 28;62(4):1817-1836. doi: 10.1021/acs.jmedchem.8b01765. Epub 2019 Feb 13.

PMID:
30689946
8.

Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.

Roelants C, Giacosa S, Pillet C, Bussat R, Champelovier P, Bastien O, Guyon L, Arnoux V, Cochet C, Filhol O.

Oncotarget. 2018 Jul 10;9(53):30066-30078. doi: 10.18632/oncotarget.25700. eCollection 2018 Jul 10. Erratum in: Oncotarget. 2019 Mar 15;10(22):2236.

9.

TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.

Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, Mojsa B, Damiano MA, Mora S, Lassot I, Ravichandran R, Cochet C, Aouacheria A, Potts PR, Herold MJ, Desagher S, Kucharczak J.

Cell Death Differ. 2019 May;26(5):902-917. doi: 10.1038/s41418-018-0169-5. Epub 2018 Jul 24.

PMID:
30042493
10.

Efficacy and safety of continuous infusions with elastomeric pumps for outpatient parenteral antimicrobial therapy (OPAT): an observational study.

Voumard R, Gardiol C, André P, Arensdorff L, Cochet C, Boillat-Blanco N, Decosterd L, Buclin T, de Vallière S.

J Antimicrob Chemother. 2018 Sep 1;73(9):2540-2545. doi: 10.1093/jac/dky224.

PMID:
29982449
11.

The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Polena H, Creuzet J, Dufies M, Sidibé A, Khalil-Mgharbel A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura C, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pages G, Vilgrain I.

Br J Cancer. 2018 May;118(9):1179-1188. doi: 10.1038/s41416-018-0054-5. Epub 2018 Mar 22.

12.

Stem Cell-Like Properties of CK2β-down Regulated Mammary Cells.

Duchemin-Pelletier E, Baulard M, Spreux E, Prioux M, Burute M, Mograbi B, Guyon L, Théry M, Cochet C, Filhol O.

Cancers (Basel). 2017 Aug 31;9(9). pii: E114. doi: 10.3390/cancers9090114.

13.

Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps.

Saillen L, Arensdorff L, Moulin E, Voumard R, Cochet C, Boillat-Blanco N, Gardiol C, de Vallière S.

Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1387-1392. doi: 10.1007/s10096-017-2944-5. Epub 2017 Mar 11.

PMID:
28283831
14.

In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface.

Bestgen B, Belaid-Choucair Z, Lomberget T, Le Borgne M, Filhol O, Cochet C.

Pharmaceuticals (Basel). 2017 Feb 3;10(1). pii: E16. doi: 10.3390/ph10010016.

15.

Antibiotic stability related to temperature variations in elastomeric pumps used for outpatient parenteral antimicrobial therapy (OPAT).

Voumard R, Van Neyghem N, Cochet C, Gardiol C, Decosterd L, Buclin T, de Valliere S.

J Antimicrob Chemother. 2017 May 1;72(5):1462-1465. doi: 10.1093/jac/dkw582.

PMID:
28158637
16.

Protein kinase CK2 controls T-cell polarization through dendritic cell activation in response to contact sensitizers.

de Bourayne M, Gallais Y, El Ali Z, Rousseau P, Damiens MH, Cochet C, Filhol O, Chollet-Martin S, Pallardy M, Kerdine-Römer S.

J Leukoc Biol. 2017 Mar;101(3):703-715. doi: 10.1189/jlb.3A0715-320RR. Epub 2016 Oct 5.

PMID:
27707883
17.

Adaptations of semen characteristics and sperm motility to harsh salinity: Extreme situations encountered by the euryhaline tilapia Sarotherodon melanotheron heudelotii (Dumeril, 1859).

Legendre M, Alavi SM, Dzyuba B, Linhart O, Prokopchuk G, Cochet C, Dugué R, Cosson J.

Theriogenology. 2016 Sep 15;86(5):1251-67. doi: 10.1016/j.theriogenology.2016.04.066. Epub 2016 Apr 25.

PMID:
27260510
18.

Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity.

Gardiol C, Voumard R, Cochet C, de Vallière S.

Eur J Clin Microbiol Infect Dis. 2016 May;35(5):839-45. doi: 10.1007/s10096-016-2606-z. Epub 2016 Feb 17.

PMID:
26886452
19.

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, Thierry AC, Mayor C, Bailer RT, Mbaya OT, Zhou Y, Ploquin A, Sullivan NJ, Graham BS, Roman F, De Ryck I, Ballou WR, Kieny MP, Moorthy V, Spertini F, Genton B.

Lancet Infect Dis. 2016 Mar;16(3):311-20. doi: 10.1016/S1473-3099(15)00486-7. Epub 2015 Dec 23.

20.

Modulatory role of the anti-apoptotic protein kinase CK2 in the sub-cellular localization of Fas associated death domain protein (FADD).

Vilmont V, Filhol O, Hesse AM, Couté Y, Hue C, Rémy-Tourneur L, Mistou S, Cochet C, Chiocchia G.

Biochim Biophys Acta. 2015 Nov;1853(11 Pt A):2885-96. doi: 10.1016/j.bbamcr.2015.08.001. Epub 2015 Aug 5.

21.

Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.

Filhol O, Giacosa S, Wallez Y, Cochet C.

Cell Mol Life Sci. 2015 Sep;72(17):3305-22. doi: 10.1007/s00018-015-1929-8. Epub 2015 May 20. Review.

PMID:
25990538
22.

[Strength and specificity of the CMBA screening platform for bioactive molecules discovery].

Barette C, Soleilhac E, Charavay C, Cochet C, Fauvarque MO.

Med Sci (Paris). 2015 Apr;31(4):423-31. doi: 10.1051/medsci/20153104017. Epub 2015 May 8. Review. French.

23.

Analysis of the black-chinned tilapia Sarotherodon melanotheron heudelotii reproducing under a wide range of salinities: from RNA-seq to candidate genes.

Avarre JC, Dugué R, Alonso P, Diombokho A, Joffrois C, Faivre N, Cochet C, Durand JD.

Mol Ecol Resour. 2014 Jan;14(1):139-49. doi: 10.1111/1755-0998.12148. Epub 2013 Jul 25.

PMID:
23889972
24.

Awareness of standard precautions for 4439 healthcare professionals in 34 institutions in France.

Atif ML, Brenet A, Hageaux S, Fave MH, Cochet C, Baticle E, Pourrier C, Wolny D, Astagneau P, Kadi Z; Standard precautions work group.

Med Mal Infect. 2013 Jan;43(1):10-6. doi: 10.1016/j.medmal.2012.11.004. Epub 2013 Jan 3.

PMID:
23290383
25.

Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E, Cochet C, Schmid RS, Lo DC, Delhommel F, Oberholzer AE, Pearl LH, Carreaux F, Bazureau JP, Knapp S, Meijer L.

J Med Chem. 2012 Nov 8;55(21):9312-30. doi: 10.1021/jm301034u. Epub 2012 Oct 8.

PMID:
22998443
26.

Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction.

Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Combes F, Vandenbrouck Y, Couté Y, Mikaelian I, Giusiano S, Charpin C, Cochet C, Filhol O.

Oncogene. 2013 Mar 14;32(11):1373-83. doi: 10.1038/onc.2012.165. Epub 2012 May 7.

PMID:
22562247
27.

Antitumoral activity of allosteric inhibitors of protein kinase CK2.

Moucadel V, Prudent R, Sautel CF, Teillet F, Barette C, Lafanechere L, Receveur-Brechot V, Cochet C.

Oncotarget. 2011 Dec;2(12):997-1010.

28.

Structure-function analysis of the beta regulatory subunit of protein kinase CK2 by targeting embryonic stem cell.

Ziercher L, Filhol O, Laudet B, Prudent R, Cochet C, Buchou T.

Mol Cell Biochem. 2011 Oct;356(1-2):75-81. doi: 10.1007/s11010-011-0955-6. Epub 2011 Aug 23.

PMID:
21861102
29.

Regulation of epithelial to mesenchymal transition: CK2β on stage.

Deshiere A, Duchemin-Pelletier E, Spreux E, Ciais D, Forcet C, Cochet C, Filhol O.

Mol Cell Biochem. 2011 Oct;356(1-2):11-20. doi: 10.1007/s11010-011-0942-y. Epub 2011 Jul 14.

PMID:
21755461
30.

Protein kinases curb cell death.

Filhol O, Cochet C.

Sci Signal. 2011 May 10;4(172):pe26. doi: 10.1126/scisignal.2001921.

PMID:
21558553
31.

NF-kappaB-mediated modulation of inducible nitric oxide synthase activity controls induction of the Epstein-Barr virus productive cycle by transforming growth factor beta 1.

Oussaief L, Ramírez V, Hippocrate A, Arbach H, Cochet C, Proust A, Raphaël M, Khelifa R, Joab I.

J Virol. 2011 Jul;85(13):6502-12. doi: 10.1128/JVI.02560-10. Epub 2011 Apr 20.

32.

Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.

Giusiano S, Cochet C, Filhol O, Duchemin-Pelletier E, Secq V, Bonnier P, Carcopino X, Boubli L, Birnbaum D, Garcia S, Iovanna J, Charpin C.

Eur J Cancer. 2011 Mar;47(5):792-801. doi: 10.1016/j.ejca.2010.11.028. Epub 2010 Dec 29.

PMID:
21194925
33.

Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2.

Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, Florent JC, Lafanechère L, Sautel CF, Duchemin-Pelletier E, Spreux E, Filhol O, Reiser JB, Cochet C.

Cancer Res. 2010 Dec 1;70(23):9865-74. doi: 10.1158/0008-5472.CAN-10-0917. Epub 2010 Nov 30.

34.

In vitro and in vivo assays of protein kinase CK2 activity.

Prudent R, Sautel CF, Moucadel V, Laudet B, Filhol O, Cochet C.

Methods Enzymol. 2010;485:597-610. doi: 10.1016/B978-0-12-381296-4.00031-2.

PMID:
21050938
35.

New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.

López-Ramos M, Prudent R, Moucadel V, Sautel CF, Barette C, Lafanechère L, Mouawad L, Grierson D, Schmidt F, Florent JC, Filippakopoulos P, Bullock AN, Knapp S, Reiser JB, Cochet C.

FASEB J. 2010 Sep;24(9):3171-85. doi: 10.1096/fj.09-143743. Epub 2010 Apr 16. Erratum in: FASEB J. 2011 May;25(5):1775.

PMID:
20400536
36.

Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon.

Huillard E, Ziercher L, Blond O, Wong M, Deloulme JC, Souchelnytskyi S, Baudier J, Cochet C, Buchou T.

Mol Cell Biol. 2010 Jun;30(11):2737-49. doi: 10.1128/MCB.01566-09. Epub 2010 Apr 5.

37.

Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2.

Prudent R, Sautel CF, Cochet C.

Biochim Biophys Acta. 2010 Mar;1804(3):493-8. doi: 10.1016/j.bbapap.2009.09.003. Epub 2009 Sep 18. Review.

PMID:
19766740
38.

Protein kinase CK2 in health and disease: Cellular functions of protein kinase CK2: a dynamic affair.

Filhol O, Cochet C.

Cell Mol Life Sci. 2009 Jun;66(11-12):1830-9. doi: 10.1007/s00018-009-9151-1. Review.

PMID:
19387551
39.

New protein kinase CK2 inhibitors: jumping out of the catalytic box.

Prudent R, Cochet C.

Chem Biol. 2009 Feb 27;16(2):112-20. doi: 10.1016/j.chembiol.2009.01.004. Review.

40.

[Polyoxometalates. A new class of inorganic CK2 inhibitors].

Prudent R, Hasenknopf B, Cochet C.

Med Sci (Paris). 2008 Dec;24(12):1012-4. doi: 10.1051/medsci/200824121012. French. No abstract available.

41.

Functional analysis of protein kinase CK2 of the human malaria parasite Plasmodium falciparum.

Holland Z, Prudent R, Reiser JB, Cochet C, Doerig C.

Eukaryot Cell. 2009 Mar;8(3):388-97. doi: 10.1128/EC.00334-08. Epub 2008 Dec 29.

42.

Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.

Prudent R, López-Ramos M, Moucadel V, Barette C, Grierson D, Mouawad L, Florent JC, Lafanechère L, Schmidt F, Cochet C.

Biochim Biophys Acta. 2008 Dec;1780(12):1412-20. doi: 10.1016/j.bbagen.2008.06.010. Epub 2008 Jul 7.

PMID:
18674590
43.

Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.

Prudent R, Moucadel V, Laudet B, Barette C, Lafanechère L, Hasenknopf B, Li J, Bareyt S, Lacôte E, Thorimbert S, Malacria M, Gouzerh P, Cochet C.

Chem Biol. 2008 Jul 21;15(7):683-92. doi: 10.1016/j.chembiol.2008.05.018.

44.

Protein kinase CK2 and cell polarity.

Deshière A, Theis-Febvre N, Martel V, Cochet C, Filhol O.

Mol Cell Biochem. 2008 Sep;316(1-2):107-13. doi: 10.1007/s11010-008-9845-y. Epub 2008 Jun 28.

PMID:
18587631
45.

Expanding the chemical diversity of CK2 inhibitors.

Prudent R, Moucadel V, López-Ramos M, Aci S, Laudet B, Mouawad L, Barette C, Einhorn J, Einhorn C, Denis JN, Bisson G, Schmidt F, Roy S, Lafanechere L, Florent JC, Cochet C.

Mol Cell Biochem. 2008 Sep;316(1-2):71-85. doi: 10.1007/s11010-008-9828-z. Epub 2008 Jun 18.

PMID:
18563535
46.

Identification of chemical inhibitors of protein-kinase CK2 subunit interaction.

Laudet B, Moucadel V, Prudent R, Filhol O, Wong YS, Royer D, Cochet C.

Mol Cell Biochem. 2008 Sep;316(1-2):63-9. doi: 10.1007/s11010-008-9821-6. Epub 2008 Jun 14.

PMID:
18553057
47.

Phosphorylation of the C subunit (p66) of human DNA polymerase delta.

Lemmens L, Urbach S, Prudent R, Cochet C, Baldacci G, Hughes P.

Biochem Biophys Res Commun. 2008 Mar 7;367(2):264-70. Epub 2007 Dec 26.

PMID:
18157942
48.

Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction.

Laudet B, Barette C, Dulery V, Renaudet O, Dumy P, Metz A, Prudent R, Deshiere A, Dideberg O, Filhol O, Cochet C.

Biochem J. 2007 Dec 15;408(3):363-73.

49.

Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles.

Medina-Palazon C, Gruffat H, Mure F, Filhol O, Vingtdeux-Didier V, Drobecq H, Cochet C, Sergeant N, Sergeant A, Manet E.

J Virol. 2007 Nov;81(21):11850-60. Epub 2007 Aug 15.

50.

[Therapeutic agents targetting protein-protein interactions: myth or reality?].

Laudet B, Prudent R, Filhol O, Cochet C.

Med Sci (Paris). 2007 Mar;23(3):273-8. Review. French.

Supplemental Content

Loading ...
Support Center